Any feedback?
Information on EC 5.3.99.5 - thromboxane-A synthase
for references in articles please use BRENDA:EC5.3.99.5Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EC Tree
5.3.99.5 thromboxane-A synthaseIUBMB Comments
A cytochrome P-450 heme-thiolate enzyme. Converts prostaglandin H2 into thromboxane A2.
Specify your search results
Word Map
- 5.3.99.5
- platelet
- prostaglandin
-
arachidonic
- artery
-
cyclooxygenase
- prostacyclin
- indomethacin
- endothelial
-
endoperoxide
- pulmonary
-
prostanoids
- aspirin
- dazoxiben
- coronary
-
eicosanoids
-
vasoconstrictor
-
leukotriene
- imidazole
- hypertension
- thrombosis
- aorta
-
hemodynamic
-
antiplatelet
-
6-keto-pgf1
- cox-2
-
5-lipoxygenase
-
6-keto-prostaglandin
-
vasodilator
-
antithrombotic
- ozagrel
-
endothelium-dependent
- thrombus
- paf
-
endothelium-derived
-
bronchoconstriction
-
6-keto
-
platelet-rich
-
constrictor
-
collagen-induced
-
aa-induced
- analysis
- medicine
-
aspirin-treated
- pharmacology
- ticlopidine
-
reocclusion
- meclofenamate
-
f1alpha
- pgg2
-
iloprost
-
antiaggregatory
-
14c-arachidonic
-
proaggregatory
The enzyme appears in viruses and cellular organisms
Reaction Schemes
Synonyms
thromboxane synthetase, thromboxane synthase, txa2 synthase, txas, thromboxane a2 synthetase, thromboxane a2 synthase, tbxas1, cyp5a1, txa synthase, thromboxane a synthase 1, 
more
topPlease wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYNONYM 
ORGANISM
UNIPROT
COMMENTARY 
LITERATURE
Synthetase, thromboxane
-
-
-
-
Thromboxan synthetase
-
-
-
-
thromboxane A2 synthase
Thromboxane A2 synthetase
-
-
-
-
thromboxane synthase
Thromboxane synthetase
-
-
-
-
TXA synthase
-
-
-
-
TXA2 synthase
TXAS
TXS
thromboxane synthase
-
-
TXAS
-
-
-
-
TXAS
-
-
TXS
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REACTION
REACTION DIAGRAM
COMMENTARY
ORGANISM
UNIPROT
LITERATURE
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate = (5Z,13E)-(15S)-9alpha,11alpha-epoxy-15-hydroxythromboxa-5,13-dienoate
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate = (5Z,13E)-(15S)-9alpha,11alpha-epoxy-15-hydroxythromboxa-5,13-dienoate
mechanism
-
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate = (5Z,13E)-(15S)-9alpha,11alpha-epoxy-15-hydroxythromboxa-5,13-dienoate
role of the thiolate ligand in the oxygen activation mechanism
-
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate = (5Z,13E)-(15S)-9alpha,11alpha-epoxy-15-hydroxythromboxa-5,13-dienoate
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
intramolecular oxidoreduction
-
-
-
-
isomerization
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PATHWAY SOURCE
PATHWAYS
BRENDA
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYSTEMATIC NAME
IUBMB Comments
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate isomerase
A cytochrome P-450 heme-thiolate enzyme. Converts prostaglandin H2 into thromboxane A2.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CAS REGISTRY NUMBER
COMMENTARY
61276-89-9
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SUBSTRATE
PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-9a,11a-epoxy-15-hydroxythromboxa-5,13-dienoate
-
-
i.e. TXA2
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-9alpha,11alpha-epoxy-15-hydroxythromboxa-5,13-dienoate
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
12-L-hydroxy-5,8,10-heptadecaotrienoic acid + malondialdehyde
15(S)-Hydroxy-11alpha,9alpha-epoxymethano-5(Z),13(E)-prostadienoic acid
?
-
in presence of iodosylbenzene
3 different hydroxylated derivatives of 15(S)-hydroxy-11alpha,9alpha-epoxymethano-5(Z),13(E)-prostadienoic acid
?
15-hydroperoxyeicosatetraenoic acid
13-hydroxy-14,15-epoxy-5,8,11-eicosatrienoic acid + 15-ketoeicosatetraenoic acid + 13-hydroxy-14,15-epoxy-5,8,11-eicosatrienoic acid + 15-ketoeicosatetraenoic acid
-
-
13-hydroxy-14,15-epoxy-5,8,11-eicosatrienoic acid and 15-ketoeicosatetraenoic acid result from homolytic cleavage of the O-O bond, whereas 13-hydroxy-14,15-epoxy-5,8,11-eicosatrienoic acid + 15-ketoeicosatetraenoic acid results from heterolytic cleavage. About 60% of substrate is cleaved homolytically, and maximal velocity of homolytic cleavage is about 1.4fold faster than heterolytic cleavage
-
?
2 prostaglandin G2
15-hydroperoxythromboxane A2 + 12-hydroperoxy-5,8,10-heptadecatrienoic acid
-
i.e. PGG2
the reaction products are transformed to thromboxane B2 and 12-hydroxy-5,8,10-heptadecatrienoic acid by SnCl2 reduction and to 12-keto-5,8,10-heptadecatrienoic acid and 15-ketothromboxane B2 by lead tetraacetate dehydration
?
2 prostaglandin G2 + H2O
15-hydroperoxythromboxane B2 + 12-hydroperoxy-5,8,10-heptadecatrienoic acid
2 prostaglandin H3 + H2O
thromboxane B3 + 12(L)-hydroxy-5,8,10,14-heptadecatetraenoic acid + malondialdehyde
-
-
the ratio of thromboxane to C17 hydroxyfatty acid formation is 1:1. Thromboxane A2 is fully transformed to thromboxane B2
?
8-Isoprostaglandin H2
8-cis-12-Hydroperoxy-5,8,10-heptadecatrienoic acid
-
-
-
?
prostaglandin E2
thromboxane A2 + ?
-
-
thromoboxane A2 is non-enzymatically converted to thromboxane B2, which is secretion is measured to analyze the enzyme activity
-
?
Prostaglandin H3
Thromboxane B3 + DELTA14-12-hydroperoxy-5,8,10-heptadecatrienoic acid
-
-
-
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-9alpha,11alpha-epoxy-15-hydroxythromboxa-5,13-dienoate
-
-
i.e. TXA2
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-9alpha,11alpha-epoxy-15-hydroxythromboxa-5,13-dienoate
-
-
-
-
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-9alpha,11alpha-epoxy-15-hydroxythromboxa-5,13-dienoate
-
-
i.e. TXA2
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-9alpha,11alpha-epoxy-15-hydroxythromboxa-5,13-dienoate
-
-
i.e. TXA2
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-9alpha,11alpha-epoxy-15-hydroxythromboxa-5,13-dienoate
-
-
i.e. TXA2
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-9alpha,11alpha-epoxy-15-hydroxythromboxa-5,13-dienoate
-
-
i.e. TXA2
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-9alpha,11alpha-epoxy-15-hydroxythromboxa-5,13-dienoate
-
-
i.e. TXA2
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-9alpha,11alpha-epoxy-15-hydroxythromboxa-5,13-dienoate
-
-
i.e. TXA2
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-9alpha,11alpha-epoxy-15-hydroxythromboxa-5,13-dienoate
-
-
i.e. TXA2
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-9alpha,11alpha-epoxy-15-hydroxythromboxa-5,13-dienoate
-
-
i.e. TXA2
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-9alpha,11alpha-epoxy-15-hydroxythromboxa-5,13-dienoate
-
-
i.e. TXA2
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-9alpha,11alpha-epoxy-15-hydroxythromboxa-5,13-dienoate
-
-
i.e. TXA2
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-9alpha,11alpha-epoxy-15-hydroxythromboxa-5,13-dienoate
-
-
i.e. TXA2
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-9alpha,11alpha-epoxy-15-hydroxythromboxa-5,13-dienoate
-
-
i.e. TXA2
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-9alpha,11alpha-epoxy-15-hydroxythromboxa-5,13-dienoate
-
-
i.e. TXA2
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
12-L-hydroxy-5,8,10-heptadecaotrienoic acid + malondialdehyde
-
-
ratio of TXA2/heptadecatrienoic acid/malondialdehyde, 1/1/1
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
12-L-hydroxy-5,8,10-heptadecaotrienoic acid + malondialdehyde
-
-
ratio of TXA2/heptadecatrienoic acid/malondialdehyde, 1/1/1
?
2 prostaglandin G2 + H2O
15-hydroperoxythromboxane B2 + 12-hydroperoxy-5,8,10-heptadecatrienoic acid
-
i.e. PGG2
-
-
?
2 prostaglandin G2 + H2O
15-hydroperoxythromboxane B2 + 12-hydroperoxy-5,8,10-heptadecatrienoic acid
-
i.e. PGG2
-
?
2 prostaglandin G2 + H2O
15-hydroperoxythromboxane B2 + 12-hydroperoxy-5,8,10-heptadecatrienoic acid
-
i.e. PGG2
-
?
prostaglandin H1
12(L)-hydroxy-8,10-heptadecadienoic acid + thromboxane B1
-
-
-
-
?
prostaglandin H1
12(L)-hydroxy-8,10-heptadecadienoic acid + thromboxane B1
-
-
thromboxane B1 is scarcely detectable, the major product is 12(L)-hydroxy-8,10-heptadecadienoic acid
?
prostaglandin H1
12(L)-hydroxy-8,10-heptadecadienoic acid + thromboxane B1
-
activity is equal to that with prostaglandin H2
thromboxane B1 is scarcely detectable, the major product is 12(L)-hydroxy-8,10-heptadecadienoic acid
?
prostaglandin H1
12(L)-hydroxy-8,10-heptadecadienoic acid + thromboxane B1
-
-
-
?
prostaglandin H1
12(L)-hydroxy-8,10-heptadecadienoic acid + thromboxane B1
-
-
thromboxane B2 is not mentioned as product
?
prostaglandin H1
12(L)-hydroxy-8,10-heptadecadienoic acid + thromboxane B1
-
-
thromboxane B1 is scarcely detectable, the major product is 12(L)-hydroxy-8,10-heptadecadienoic acid
?
prostaglandin H1
12(L)-hydroxy-8,10-heptadecadienoic acid + thromboxane B1
-
-
thromboxane B1 is scarcely detectable, the major product is 12(L)-hydroxy-8,10-heptadecadienoic acid
?
prostaglandin H1
12(L)-hydroxy-8,10-heptadecadienoic acid + thromboxane B1
-
poor substrate
-
-
?
Prostaglandin H2
thromboxane B2 + 12(L)-hydroxy-5,8,10-heptadecatrienoic acid
-
i.e. PGH2
-
-
?
Prostaglandin H2
thromboxane B2 + 12(L)-hydroxy-5,8,10-heptadecatrienoic acid
-
i.e. PGH2
-
?
Prostaglandin H2
thromboxane B2 + 12(L)-hydroxy-5,8,10-heptadecatrienoic acid
-
i.e. PGH2
-
?
Prostaglandin H2
thromboxane B2 + 12(L)-hydroxy-5,8,10-heptadecatrienoic acid
-
i.e. PGH2
-
-
?
Prostaglandin H2
thromboxane B2 + 12(L)-hydroxy-5,8,10-heptadecatrienoic acid
-
i.e. PGH2
-
-
?
Prostaglandin H2
thromboxane B2 + 12(L)-hydroxy-5,8,10-heptadecatrienoic acid
-
i.e. PGH2
-
?
Prostaglandin H2
thromboxane B2 + 12(L)-hydroxy-5,8,10-heptadecatrienoic acid
-
i.e. PGH2
-
-
?
Prostaglandin H2
thromboxane B2 + 12(L)-hydroxy-5,8,10-heptadecatrienoic acid
-
i.e. PGH2
-
?
Prostaglandin H2
thromboxane B2 + 12(L)-hydroxy-5,8,10-heptadecatrienoic acid
-
i.e. PGH2
-
-
?
Prostaglandin H2
thromboxane B2 + 12(L)-hydroxy-5,8,10-heptadecatrienoic acid
-
i.e. PGH2
-
?
Prostaglandin H2
thromboxane B2 + 12(L)-hydroxy-5,8,10-heptadecatrienoic acid
-
i.e. PGH2
-
-
?
Prostaglandin H2
thromboxane B2 + 12(L)-hydroxy-5,8,10-heptadecatrienoic acid
-
i.e. PGH2
the thromboxane A2 that is formed by the enzyme is transformed to thromboxane B2
?
Prostaglandin H2
thromboxane B2 + 12(L)-hydroxy-5,8,10-heptadecatrienoic acid
-
i.e. PGH2
the thromboxane A2 that is formed by the enzyme is transformed to thromboxane B2
?
Prostaglandin H2
thromboxane B2 + 12(L)-hydroxy-5,8,10-heptadecatrienoic acid
-
i.e. PGH2
+ malondialdehyde
?
Prostaglandin H2
thromboxane B2 + 12(L)-hydroxy-5,8,10-heptadecatrienoic acid
-
i.e. PGH2
+ malondialdehyde
?
Prostaglandin H2
thromboxane B2 + 12(L)-hydroxy-5,8,10-heptadecatrienoic acid
-
i.e. PGH2
the ratio of thromboxane to C17 hydroxyfatty acid formation is 1:1
?
Prostaglandin H2
thromboxane B2 + 12(L)-hydroxy-5,8,10-heptadecatrienoic acid
-
i.e. PGH2
the ratio of thromboxane to C17 hydroxyfatty acid formation is 1:1
?
Prostaglandin H2
thromboxane B2 + 12(L)-hydroxy-5,8,10-heptadecatrienoic acid
-
i.e. PGH2
the ratio of thromboxane to C17 hydroxyfatty acid formation is 1:1
?
Prostaglandin H2
thromboxane B2 + 12(L)-hydroxy-5,8,10-heptadecatrienoic acid
-
i.e. PGH2
thromboxane A2 is an intermediate
?
Prostaglandin H2
thromboxane B2 + 12(L)-hydroxy-5,8,10-heptadecatrienoic acid
-
i.e. PGH2
-
-
?
Prostaglandin H2
thromboxane B2 + 12(L)-hydroxy-5,8,10-heptadecatrienoic acid
-
i.e. PGH2
-
-
?
Prostaglandin H2
thromboxane B2 + 12(L)-hydroxy-5,8,10-heptadecatrienoic acid
-
i.e. PGH2
-
-
?
Prostaglandin H2
thromboxane B2 + 12(L)-hydroxy-5,8,10-heptadecatrienoic acid
-
i.e. PGH2
-
-
?
Prostaglandin H2
thromboxane B2 + 12(L)-hydroxy-5,8,10-heptadecatrienoic acid
-
i.e. PGH2
-
?
Prostaglandin H2
thromboxane B2 + 12(L)-hydroxy-5,8,10-heptadecatrienoic acid
-
i.e. PGH2
-
?
Prostaglandin H2
thromboxane B2 + 12(L)-hydroxy-5,8,10-heptadecatrienoic acid
-
i.e. PGH2
the ratio of 12-hydroxy-5,8,10-heptadecatrienoic acid to thromboxane B2 varries from 1.6 to 2.1 depending on the reaction conditions
?
prostaglandin H2
thromboxane B2 + 12(S)-hydroxy-5,8,10-heptadecatrienoic acid
-
-
-
-
?
prostaglandin H2
thromboxane B2 + 12(S)-hydroxy-5,8,10-heptadecatrienoic acid
-
-
-
-
?
prostaglandin H2
thromboxane B2 + 12(S)-hydroxy-5,8,10-heptadecatrienoic acid
-
-
-
-
?
additional information
?
-
-
production of thromboxane A2, an unstable bioregulator that induces platelet release reaction, platelet aggregation and smooth muscle contraction
-
-
?
additional information
?
-
-
cyclooxygenase-2 and thromboxane synthase are involved in the diosgenin-induced megakaryocytic differentiation in HEL cells
for analysis of the thromboxane synthase activity the secretion of thromoxane B2 is measured. Thromboxane B2 is a nonenzymatic conversion product of thromobxane A1, the product of the thromboxane synthase activity
-
?
additional information
?
-
-
TXAS is one of the terminal enzymes of the arachidonic acid cascade and converts prostaglandins H2 into thromobane A2 in the endoplasmic reticulum
-
-
?
additional information
?
-
-
thromboxane A2 synthase catalyzes an isomerization of prostaglandins H2 to give rise to thromboxane A2 along with a fragmentation reaction to 12-L-hydroxy-5,8,10-heptadecatrienoic acid and malondialdehyde. 2-p-Toluidinylnaphthalene-6-sulfonic acid is utilized as a probe to assess the spatial relationship and binding dynamics of ligand-enzyme interactions by steady-state and time-resolved fluorescence spectroscopy
-
-
?
additional information
?
-
-
substrate binding analysis using substrate analogues of PGH2, U44069 and U46619
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
NATURAL SUBSTRATE
NATURAL PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-9alpha,11alpha-epoxy-15-hydroxythromboxa-5,13-dienoate
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
12-L-hydroxy-5,8,10-heptadecaotrienoic acid + malondialdehyde
prostaglandin H2
thromboxane B2 + 12(S)-hydroxy-5,8,10-heptadecatrienoic acid
-
-
-
-
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-9alpha,11alpha-epoxy-15-hydroxythromboxa-5,13-dienoate
-
-
i.e. TXA2
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-9alpha,11alpha-epoxy-15-hydroxythromboxa-5,13-dienoate
-
-
-
-
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-9alpha,11alpha-epoxy-15-hydroxythromboxa-5,13-dienoate
-
-
i.e. TXA2
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-9alpha,11alpha-epoxy-15-hydroxythromboxa-5,13-dienoate
-
-
i.e. TXA2
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-9alpha,11alpha-epoxy-15-hydroxythromboxa-5,13-dienoate
-
-
i.e. TXA2
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-9alpha,11alpha-epoxy-15-hydroxythromboxa-5,13-dienoate
-
-
i.e. TXA2
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-9alpha,11alpha-epoxy-15-hydroxythromboxa-5,13-dienoate
-
-
i.e. TXA2
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-9alpha,11alpha-epoxy-15-hydroxythromboxa-5,13-dienoate
-
-
i.e. TXA2
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-9alpha,11alpha-epoxy-15-hydroxythromboxa-5,13-dienoate
-
-
i.e. TXA2
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-9alpha,11alpha-epoxy-15-hydroxythromboxa-5,13-dienoate
-
-
i.e. TXA2
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-9alpha,11alpha-epoxy-15-hydroxythromboxa-5,13-dienoate
-
-
i.e. TXA2
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-9alpha,11alpha-epoxy-15-hydroxythromboxa-5,13-dienoate
-
-
i.e. TXA2
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-9alpha,11alpha-epoxy-15-hydroxythromboxa-5,13-dienoate
-
-
i.e. TXA2
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-9alpha,11alpha-epoxy-15-hydroxythromboxa-5,13-dienoate
-
-
i.e. TXA2
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-9alpha,11alpha-epoxy-15-hydroxythromboxa-5,13-dienoate
-
-
i.e. TXA2
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
12-L-hydroxy-5,8,10-heptadecaotrienoic acid + malondialdehyde
-
-
ratio of TXA2/heptadecatrienoic acid/malondialdehyde, 1/1/1
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
12-L-hydroxy-5,8,10-heptadecaotrienoic acid + malondialdehyde
-
-
ratio of TXA2/heptadecatrienoic acid/malondialdehyde, 1/1/1
?
additional information
?
-
-
production of thromboxane A2, an unstable bioregulator that induces platelet release reaction, platelet aggregation and smooth muscle contraction
-
-
?
additional information
?
-
-
cyclooxygenase-2 and thromboxane synthase are involved in the diosgenin-induced megakaryocytic differentiation in HEL cells
for analysis of the thromboxane synthase activity the secretion of thromoxane B2 is measured. Thromboxane B2 is a nonenzymatic conversion product of thromobxane A1, the product of the thromboxane synthase activity
-
?
additional information
?
-
-
TXAS is one of the terminal enzymes of the arachidonic acid cascade and converts prostaglandins H2 into thromobane A2 in the endoplasmic reticulum
-
-
?
additional information
?
-
-
thromboxane A2 synthase catalyzes an isomerization of prostaglandins H2 to give rise to thromboxane A2 along with a fragmentation reaction to 12-L-hydroxy-5,8,10-heptadecatrienoic acid and malondialdehyde. 2-p-Toluidinylnaphthalene-6-sulfonic acid is utilized as a probe to assess the spatial relationship and binding dynamics of ligand-enzyme interactions by steady-state and time-resolved fluorescence spectroscopy
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
COFACTOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
heme
-
the heme-thiolate group of the enzyme is required to split and activate the endoperoxide bond of prostaglandin H2
heme
-
contains one heme per 58000 MW protein. The major part of the enzyme is converted by the elution procedure to the inactive P420 form, a minor part is in its native heme-thiolate conformation
heme
-
comparison of thromboxane A2 synthase model based on the P450BM-3 with another thromboxane A2 synthase model based on the P450cam structure indicates that P450BM-3 is a more suitable template for homology modeling of thromboxane A2 synthase. P450BM-3 and p450cam are hemoprotein domains of cytochrome
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
additional information
-
cyanide binding to substrate-free and substrate-bound CYP5A1 in a detergent-solubilized system and in nanodiscs, binding kinetics, overview
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
(+)-(E)-7-[4-[4-[[[2-(trans)-phenylcyclopropyl]amino]carbonyl]-2-oxazolyl]phenyl]-7-(3-pyridyl)hept-6-enoic acid
-
0.0000085 mM, 50% inhibition
(+)-5-(2-imidazole-1-ethyloxy)-1-indan-carboxylic acid
-
trivial name camonagrel
(+/-)-6-(1-Imidazolylmethyl)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid hydrochloride hemihydrate
-
improvement of the renal function with the selective thromboxane A2 synthetase inhibitor
(-)-(E)-7-[4-[4-[[[2-(trans)-phenylcyclopropyl]amino]carbonyl]-2-oxazolyl]phenyl]-7-(3-pyridyl)hept-6-enoic acid
-
0.0000059 mM, 50% inhibition
(5E)-6-(3-(2-cyano-3,3-dimethyl)guanidinophenyl)-6-(3-pyridyl)hex-5-enoic acid
-
0.000026 mM, 50% inhibition
(5E)-6-(3-(2-cyano-3-(1-adamantyl)-guanidino)phenyl)-6-(3-pyridyl)hex-5-enoic acid
-
0.000003 mM, 50% inhibition
(5E)-6-(3-(2-cyano-3-(2-dimethylaminoethyl)-guanidino)phenyl)-6-(3-pyridyl)hex-5-enoic acid
-
0.0029 mM, 50% inhibition
(5E)-6-(3-(2-cyano-3-(2-methylpropyl)guanidino)phenyl)-6-(3-pyridyl)hex-5-enoic acid
-
0.000025 mM, 50% inhibition
(5E)-6-(3-(2-cyano-3-(3-methylbutyl)guanidino)phenyl)-6-(3-pyridyl)hex-5-enoic acid
-
0.000003 mM, 50% inhibition
(5E)-6-(3-(2-cyano-3-(3-pyridylmethyl)-guanidino)phenyl)-6-(3-pyridyl)hex-5-enoic acid
-
0.000032 mM, 50% inhibition
(5E)-6-(3-(2-cyano-3-benzylguanidino)phenyl)-6-(3-pyridyl)hex-5-enoic acid
-
0.000011 mM, 50% inhibition
(5E)-6-(3-(2-cyano-3-cyclohexyl-guanidino)phenyl)-6-(3-pyridyl)hex-5-enoic acid
-
0.000003 mM, 50% inhibition
(5E)-6-(3-(2-cyano-3-cyclopentyl-guanidino)phenyl)-6-(3-pyridyl)hex-5-enoic acid
-
0.000003 mM, 50% inhibition
(5E)-6-(3-(2-cyano-3-cyclopropyl-guanidino)phenyl)-6-(3-pyridyl)hex-5-enoic acid
-
0.00038 mM, 50% inhibition
(5E)-6-(3-(2-cyano-3-isopropyl)guanidinophenyl)-6-(3-pyridyl)hex-5-enoic acid
-
0.000024 mM, 50% inhibition
(5E)-6-(3-(2-cyano-3-methyl)guanidinophenyl)-6-(3-pyridyl)hex-5-enoic acid
-
0.00025 mM, 50% inhibition
(5E)-6-(3-(2-cyano-3-tert-butyl-guanidino)phenyl)-6-(3-pyridyl)hex-5-enoic acid
-
0.000004 mM, 50% inhibition
(5E)-6-(4-(2-cyano-3-cyclopentyl-guanidino)phenyl)-6-(3-pyridyl)hex-5-enoic acid
-
0.00018 mM, 50% inhibition
(5E)-6-(4-(2-cyano-3-cyclopropyl-guanidino)phenyl)-6-(3-pyridyl)hex-5-enoic acid
-
0.0039 mM, 50% inhibition
(5Z)-6-[(2S,4R)-4-(4-Chlorophenylsulphonylamino)-1-(3-pyridylmethyl)-2-pyrrolidinyl]-5-hexenoic acid hydrochloride
-
thromboxane A2 synthetase inhibitor/thromboxane A2-receptor antagonist
(E)-6-[4-(3-tert-butyl-2-cyanoguanidino)phenyl]-6-(3-pyridyl)hex-5-enoic acid
-
trivial name terbogrel
(E)-7-[4-[4-[(benzylamino)carbonyl]-2-oxazolyl]phenyl]-7-(3-pyridyl)hept-6-enoic acid
-
0.000025 mM, 50% inhibition
(E)-7-[4-[4-[(pentylamino)carbonyl]-2-oxazolyl]phenyl]-7-(3-pyridiyl)hept-6-enoic acid
-
0.000031 mM, 50% inhibition
(E)-7-[4-[4-[(phenylethylamino)carbonyl]-2-oxazolyl]phenyl]-7-(3-pyridyl)hept-6-enoic acid
-
0.0000094 mM, 50% inhibition
(E)-7-[4-[4-[[(2-phenoxybutyl)amino]carbonyl]-2-oxazolyl]phenyl]-7-(3-pyridyl)hept-6-enoic acid
-
0.000049 mM, 50% inhibition
(E)-7-[4-[4-[[(2-phenoxyethyl)amino]carbonyl]-2-oxazolyl]phenyl]-7-(3-pyridyl)hept-6-enoic acid
-
0.0000026 mM, 50% inhibition
(E)-7-[4-[4-[[(2-phenoxypentyl)amino]carbonyl]-2-oxazolyl]phenyl]-7-(3-pyridyl)hept-6-enoic acid
-
0.000049 mM, 50% inhibition
(E)-7-[4-[4-[[(4-cyclohexylbutyl)amino]carbonyl]-2-oxazolyl]phenyl]-7-(3-pyridyl)hept-6-enoic acid
-
0.000055 mM, 50% inhibition
(E)-7-[4-[4-[[(4-cyclopropylmethyl)amino]carbonyl]-2-oxazolyl]phenyl]-7-(3-pyridyl)hept-6-enoic acid
-
0.000025 mM, 50% inhibition
(E)-7-[4-[4-[[3-(morpholinopropyl)amino]carbonyl]-2-oxazolyl]phenyl]-7-(3-pyridyl)hept-6-enoic acid
-
0.0000051 mM, 50% inhibition
(E)-7-[4-[4-[[[2-(benzyloxy)ethyl]amino]carbonyl]-2-oxazolyl]phenyl]-7-(3-pyridyl)hept-6-enoic acid
-
0.000048 mM, 50% inhibition
(E)-7-[4-[4-[[[2-(cyclohexylmethoxy)ethyl]amino]carbonyl]-2-oxazolyl]phenyl]-7-(3-pyridyl)hept-6-enoic acid
-
0.0000037 mM, 50% inhibition
(E)-7-[4-[4-[[[2-(cyclohexyloxy)ethyl]amino]carbonyl]-2-oxazolyl]phenyl]-7-(3-pyridyl)hept-6-enoic acid
-
0.0000033 mM, 50% inhibition
(E)-7-[4-[4-[[[2-(tetrahydropyran-2-ylmethoxy)ethyl]amino]carbonyl]-2-oxazolyl]phenyl]-7-(3-pyridyl)hept-6-enoic acid
-
0.0000063 mM, 50% inhibition
(E)-7-[4-[4-[[[3-(1-cyclohexylethoxy)propyl]amino]carbonyl]-2-oxazolyl]phenyl]-7-(3-pyridyl)hept-6-enoic acid
-
0.0000012 mM, 50% inhibition
(E)-7-[4-[4-[[[3-(4-methoxyphenyl)propyl]amino]carbonyl]-2-oxazolyl]phenyl]-7-(3-pyridyl)hept-6-enoic acid
-
0.0000027 mM, 50% inhibition
(E)-7-[4-[4-[[[3-(cyclohexyloxy)propyl]amino]carbonyl]-2-oxazolyl]phenyl]-7-(3-pyridyl)hept-6-enoic acid
-
0.0000042 mM, 50% inhibition
(E)-7-[4-[4-[[[3-[(cis)-4-methoxycyclohexyl]propyl]amino]carbonyl]-2-oxazolyl]phenyl]-7-(3-pyridyl)hept-6-enoic acid
-
0.0000029 mM, 50% inhibition
(E)-7-[4-[4-[[[4-(cyclohexyloxy)butyl]amino]carbonyl]-2-oxazolyl]phenyl]-7-(3-pyridyl)hept-6-enoic acid
-
0.0000049 mM, 50% inhibition
([5-[2-([[(1E)-phenyl(pyridin-3-yl)methylidene]amino]oxy)ethyl]-7,8-dihydronaphthalen-1-yl]oxy)acetic acid
-
i.e. ONO-1301, in addition to inhibitory activity, application of ONO-1301 significantly attenuates the development of pulmonary fibrosis and improves survival after treatment with bleomycin
1-[2-(4,5,6,7-tetrahydrobenzo[b]furan-4-yl)ethyl]-1H-imidazole
-
0.001 mM, 50% inhibition
1-[2-(4,5,6,7-tetrahydrobenzo[b]furan-4-ylidene)ethyl]-1H-imidazole
-
E isomer, 0.00355 mM, 50% inhibition; Z isomer, 0.0041 mM, 50% inhibition
1-[2-(4,5,6,7-tetrahydrobenzo[b]thiophen-4-yl)ethyl]-1H-imidazole
-
0.0012 mM, 50% inhibition
1-[2-(4,5,6,7-tetrahydrobenzo[b]thiophen-4-ylidene)ethyl]-1H-imidazole
-
E isomer, 0.0017 mM, 50% inhibition; Z isomer, 0.0013 mM, 50% inhibition
1-[3-(4-Benzylhydryl-1-piperazinyl)propyl]-3-(1H-imidazol-1-ylmethyl)-1H-indole-6-carboxylic acid
-
strong thromboxane synthetase inhibition and H1-blocking activity
15-Hydroxy-9alpha,11alpha-peroxidoprosta-5,13-dienoic acid
-
irreversible inactivation during catalysis, protection by (E)-3-[4-(1-imidazolylmethyl)phenyl]-2-propenoate and 15-hydroxy-11alpha,9alpha-(epoxymethano)-prosta-5,13-dienoic acid
1H-Imidazol-1-ylalyl-substituted 3-[2-[(arylsulfonyl)amino]ethyl]benzenepropanoic acid derivatives
-
dual thromboxane synthase inhibitor/thromboxane receptor antagonists
2-[4-Carboxy-8-(5-imidazol[1,5-a]pyridinyl)octanoyl]-2,3-dihydro-1H-1-isoindole-1-carboxylic acid
-
-
2-[[1-(Carboxymethyl)-2,3,4,5,-tetrahydro-2-oxo-1H-1-benzazepin-3-yl]amino]-6-[[5-[5-chloro-1-methyl-2-(3-pyridinyl)-1H-indol-3-yl]pentanoyl]amino]hexanoic acid
-
-
2-[[1-(Carboxymethyl)-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3-yl]amino]6-[[5-[5-chloro-1-methyl-2-(3-pyridinyl)-1H-indol-3-yl]pentanoyl](2-hydroxyethyl)amino]hexanoic acid
-
-